3,5-dichloro-pyridine-2-carboxylic acid [3-((S)-3-amino-5-ethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]amide | 1346147-01-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-dichloro-pyridine-2-carboxylic acid [3-((S)-3-amino-5-ethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]amide
• 英文别名: N-[3-[(5S)-3-amino-5-ethyl-6,7-dihydro-2H-1,4-oxazepin-5-yl]-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide
• CAS: 1346147-01-0
• 化学式: C₁₉H₁₉Cl₂FN₄O₂
• 分子量: 425.29
• InChiKey: QTBHXTBCRLCBRX-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  89.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS<br/>[FR] COMPOSÉS DE 2,5,6,7-TÉTRAHYDRO-[1,4]OXAZÉPIN-3-YLAMINE OU DE 2,3,6,7-TÉTRAHYDRO-[1,4]OXAZÉPIN-5-YLAMINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011138293A1

  公开（公告）日：2011-11-10

  This invention relates to compounds of the formula (I), wherein A, B and R1 to R7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as 5 medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

  这项发明涉及式(I)的化合物，其中A、B和R1至R7如下所述，或其药学上可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作治疗和/或预防治疗阿尔茨海默病、糖尿病，特别是2型糖尿病，以及其他代谢紊乱疾病的药物。
• 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS
  申请人：Banner David

  公开号：US20110312937A1

  公开（公告）日：2011-12-22

  This invention relates to compounds of the formula wherein A, B and R 1 to R 7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

  这项发明涉及以下式的化合物 其中A、B和R1至R7如下所述，或其药学上可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作治疗和/或预防治疗阿尔茨海默病、糖尿病，特别是2型糖尿病，以及其他代谢紊乱疾病的药物。
• 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US20140045820A1

  公开（公告）日：2014-02-13

  This invention relates to compounds of the formula wherein A, B and R 1 to R 7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

  本发明涉及以下式子中的化合物，其中A，B和R1至R7如下所述，或其药学上可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作药物治疗和/或预防治疗阿尔茨海默病、糖尿病，特别是2型糖尿病和其他代谢性疾病。
• US8673894B2
  申请人：——

  公开号：US8673894B2

  公开（公告）日：2014-03-18